As­cendis Phar­ma of­fers pos­i­tive sur­prise as its tech not just equals, but im­proves out­comes in key study

Tech­nol­o­gy de­vel­oped by Den­mark’s As­cendis Phar­ma to re­lease a par­tic­u­lar drug with­in the body in a pre­dictable man­ner at reg­u­lar in­ter­vals with­out the need for mul­ti­ple sep­a­rate ad­min­is­tra­tions has been shown to work well in a late-stage tri­al in pe­di­atric pa­tients with growth hor­mone de­fi­cien­cy — val­i­dat­ing the com­pa­ny’s plat­form that is used across its port­fo­lio.

The tech­nol­o­gy, called TransCon or tran­sient con­ju­ga­tion, com­pris­es an un­mod­i­fied ap­proved drug, an in­ert car­ri­er that pro­tects it, and a link­er that tem­porar­i­ly binds the two. When bound, the car­ri­er in­ac­ti­vates and shields the par­ent drug from be­ing re­leased, but once the prod­uct is in­ject­ed in­to the body, phys­i­o­log­ic pH and tem­per­a­ture con­di­tions al­low for the pre­dictable dis­sem­i­na­tion of the ac­tive drug — this can be done dai­ly or even half year­ly. The tech can be used for sys­temic ad­min­is­tra­tion or lo­cal­ly in ar­eas that are dif­fi­cult to treat with con­ven­tion­al ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER